Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05567094
Other study ID # PANDEX-1
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 8, 2022
Est. completion date September 14, 2023

Study information

Verified date September 2023
Source Ruijin Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this clinical trial is evaluate the effect of dexamethasone on postoperative complications after pancreaticoduodenectomy.


Description:

This is a multicentric, prospective, randomized, double-blind, pragmatic, placebo-control study. Patients who are going to receive elective pancreaticoduodenectomy will be randomized to receive 0.2 mg/kg dexamethasone or saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia. The primary outcome is the Comprehensive Complication Index (CCI) score within 30 days after the operation, which will be compared between these two groups .


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date September 14, 2023
Est. primary completion date September 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult patients =18 years of age; 2. An indication for elective PD surgery; 3. Patients understand the nature of this trial and are willing to comply; 4. Patients are able to provide written informed consent; Exclusion Criteria: 1. Current or recent (within preceding 1 month) systemic use of glucocorticoids; 2. Distant metastases including peritoneal carcinomatosis, liver metastases, distant lymph node metastases, and involvement of other organs; 3. Patients may undergo left, central, or total pancreatectomy other than PD; 4. Palliative surgery; 5. Patients with high operative risk, as defined by the American Society of Anesthesiologists (ASA), with a score = 4; 6. Synchronous malignancy in other organs or second cancer requiring resection during the same procedure; 7. Pregnant and lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexamethasone
Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Saline placebo
Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia

Locations

Country Name City State
China Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Asehnoune K, Le Moal C, Lebuffe G, Le Penndu M, Josse NC, Boisson M, Lescot T, Faucher M, Jaber S, Godet T, Leone M, Motamed C, David JS, Cinotti R, El Amine Y, Liutkus D, Garot M, Marc A, Le Corre A, Thomasseau A, Jobert A, Flet L, Feuillet F, Pere M, Futier E, Roquilly A; PACMAN study group. Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial. BMJ. 2021 Jun 2;373:n1162. doi: 10.1136/bmj.n1162. — View Citation

Chen H, Wang C, Shen Z, Wang W, Weng Y, Ying X, Deng X, Shen B. Postpancreatectomy Acute Pancreatitis After Pancreaticoduodenectomy: A Distinct Clinical Entity. Ann Surg. 2023 Aug 1;278(2):e278-e283. doi: 10.1097/SLA.0000000000005605. Epub 2022 Jul 18. — View Citation

Corcoran TB, Myles PS, Forbes AB, Cheng AC, Bach LA, O'Loughlin E, Leslie K, Chan MTV, Story D, Short TG, Martin C, Coutts P, Ho KM; PADDI Investigators; Australian and New Zealand College of Anaesthetists Clinical Trials Network; Australasian Society for Infectious Diseases Clinical Research Network. Dexamethasone and Surgical-Site Infection. N Engl J Med. 2021 May 6;384(18):1731-1741. doi: 10.1056/NEJMoa2028982. — View Citation

DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ. 2017 Apr 18;357:j1455. doi: 10.1136/bmj.j1455. — View Citation

Laaninen M, Sand J, Nordback I, Vasama K, Laukkarinen J. Perioperative Hydrocortisone Reduces Major Complications After Pancreaticoduodenectomy: A Randomized Controlled Trial. Ann Surg. 2016 Nov;264(5):696-702. doi: 10.1097/SLA.0000000000001883. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The Comprehensive Complication Index (CCI) The Comprehensive Complication Index (CCI) score within 30 days after the operation.
The CCI takes into account all cumulative complications and receives values between 0 and 100. The weight of complication (wC) of the CCI is based on the established Clavien-Dindo classification.
Within 30 days after the operation
Secondary The incidence of major complications (Clavien-Dindo=3) 30 days
Secondary The incidence of postoperative pancreatic fistula (ISGPS classification) 30 days
Secondary The incidence of postpancreatectomy acute pancreatitis (ISGPS classification) 30 days
Secondary The incidence of infection (including wound infection and intra-abdominal abscess) 30 days
Secondary Postoperative length of stay 1 day of discharge
Secondary The incidence of relaparotomy 30 days
Secondary Mortality 30 days
Secondary Mortality 60 days
See also
  Status Clinical Trial Phase
Completed NCT00827931 - Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery Phase 4
Recruiting NCT05523713 - Development and Validation of a Predictive Score for Surgical Site Infections Phase 3
Completed NCT01988519 - Randomized Controlled Trial Comparing Closed-suction Drain Versus Passive Gravity Drain Following Pancreatic Resection N/A
Completed NCT01758172 - Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy Phase 3
Recruiting NCT04118881 - Ear Acupuncture Preventing Delayed Gastric Emptying. N/A
Recruiting NCT04798560 - Identifing Risk Factors for Pancreaticojejunostomy Leakage Following Pancreaticoduodenectomy
Recruiting NCT04559269 - Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
Recruiting NCT06119880 - The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy Phase 4
Not yet recruiting NCT05389917 - Three-Dimensional Vascular Reconstruction of the Pancreas on Multidetector Computed Tomography Images and Its Impact on Patients Undergoing Pancreaticoduodenectomy
Completed NCT02807701 - Minimally Invasive Pancreatico-duodenectomy N/A
Recruiting NCT01428050 - The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy Phase 2
Completed NCT00668876 - Effects of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Phase 4
Recruiting NCT06322680 - Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy N/A
Not yet recruiting NCT05314244 - Comparison Between Pylorus-resecting and Preserving Pancreaticoduodenectomy on Delayed Gastric Emptying and Nutrition N/A
Not yet recruiting NCT06123169 - Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent Phase 3
Completed NCT00931554 - Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections N/A
Completed NCT00200148 - Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy Phase 3
Recruiting NCT04342923 - Early POstoperative BIomarkers in PancreatoDuodenectomy: a Spanish Nationwide Study
Recruiting NCT03785743 - Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma N/A
Completed NCT03791450 - Investigation of Pancreaticoduodenectomy